Vetoquinol SA

Paris Stock Exchange VETO.PA

Vetoquinol SA Revenue for the year ending December 31, 2023: USD 584.18 M

Vetoquinol SA Revenue is USD 584.18 M for the year ending December 31, 2023, a 1.15% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Vetoquinol SA Revenue for the year ending December 31, 2022 was USD 577.53 M, a -2.67% change year over year.
Vetoquinol SA Revenue for the year ending December 31, 2021 was USD 593.39 M, a 13.64% change year over year.
Vetoquinol SA Revenue for the year ending December 31, 2020 was USD 522.18 M, a 17.50% change year over year.
Vetoquinol SA Revenue for the year ending December 31, 2019 was USD 444.39 M, a 5.53% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Paris Stock Exchange: VETO.PA

Vetoquinol SA

CEO	Mr. Alain Masson
IPO Date	Nov. 17, 2006
Location	France
Headquarters	Magny-Vernois
Employees	2,519
Sector	Health Care
Industries Pharmaceuticals

Description

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

Key trends

Past 5 years